Abstract:Retinoid X receptor (RXR) modulators (rexinoids) are considered to have therapeutic potential for multiple diseases, such as Alzheimer's disease and Parkinson's disease. To overcome various disadvantages of prior screening methods, we previously developed an RXR binding assay using a fluorescent RXR ligand, CU-6PMN (4). However, this ligand binds not only at the ligand-binding domain (LBD) but also at the dimer–dimer interface of hRXRα. Here, we present a new fluorescent RXR antagonist 6-[N-ethyl-N-(5-isobutoxy-4-isopropyl-2-(11-oxo-2,3,6,7-tetrahydro-1H,5H,11H-pyrano[2,3-f]pyrido[3,2,1-ij]quinoline-10-carboxamido)phenyl)amino]nicotinic acid (NEt-C343, 7), which emits strong fluorescence only when bound to the RXR-LBD. It allows us to perform a rapid, simple, and nonhazardous binding assay that does not require bound/free separation and uses a standard plate reader. The obtained Ki values of known compounds were correlated with the Ki values obtained using the standard [3H]9cis-retinoic acid assay. This assay should be useful for drug discovery as well as for research on endocrine disruptors, functional foods, and natural products.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.jmedchem.0c01883?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.jmedchem.0c01883</a>.Preparation of human RXRα-LBD, creation of human RXRα ligand-binding domain (LBD) coordinates, coordinates for compounds (input files), creating the grid box, creating input files and log files of docking simulations, calculation of the Z′ factor, statistical analysis, Schild analysis of 6 and 7 for hRXRα, transactivation of hRXR subtypes by 17 in the absence or presence of 7, UV–vis absorbance and fluorescence spectra of fluorescein and 7, relative fluorescence intensity data of 100 nM 7 in various solvents, chemical structure of CBTF-EE (19), binding assay protocol for rexinoids using 7 (λEx = 430 nm/λEm = 535 nm), time course of Z′ factors during the competitive binding assay using 100 nM 7 with 500 nM hRXRα-LBD, chemical structures of rexinoids in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>B and natural ligands in <a class="internalNav" href="#fig5">Figure </a><a class="internalNav" href="#fig5">5</a>C, fluorescence binding assay using 7 (λEx = 485 nm/λEm = 535 nm), Schild plot slopes for 6 and 7 against 17, calculated Ki values obtained with 4, 7, and 9cis-RA, lists of PDB files, supporting movie legend, NMR spectra and HPLC charts (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_001.pdf">PDF</a>)Binding model of 7 (green stick model) in the antagonistic form with RXRα-LBD (PDB code: 3A9E) on AutoDock vina (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_002.mov">MOV</a>)RXR_LBD 3A9E.pdb (chain A from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_003.pdb">PDB</a>)Cpnd 5_mode1.pdb (mode 1 structure of NEt-SB (5) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_004.pdb">PDB</a>)Cpnd 6_mode1.pdb (mode 1 structure of NEt-BA (6) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_005.pdb">PDB</a>)Cpnd 6_mode2.pdb (mode 1 structure of NEt-BA (6) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_006.pdb">PDB</a>)Cpnd 7_mode1.pdb (mode 1 structure of NEt-C343 (7) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_007.pdb">PDB</a>)Cpnd 7_mode6.pdb (mode 6 structure of NEt-C343 (7) in RXR_LBD after docking) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_008.pdb">PDB</a>)LG_3A9E.pdb (binding structure of LG100754 (18) "754" from pdb. 3A9E) (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_009.pdb">PDB</a>)Molecular formula strings and some data (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.0c01883/suppl_file/jm0c01883_si_010.csv">CSV</a>)This article has not yet been cited by other publications.

Supplementary Methods from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 6 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 3 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 7 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 2 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 1 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 5 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

Supplementary Figure 4 from RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2

RXRα Inhibits the NRF2-ARE Signaling Pathway Through a Direct Interaction with the Neh7 Domain of NRF2.

Rexinoid Inhibits Nrf2-Mediated Transcription Through Retinoid X Receptor Alpha

Structural Basis for Retinoic X Receptor Repression on the Tetramer

The Short Isoform of PML‐RARα Activates the NRF2/HO‐1 Pathway Through a Direct Interaction with NRF2

Supplementary Figure Legend from Generation of a Stable Antioxidant Response Element–Driven Reporter Gene Cell Line and Its Use to Show Redox-Dependent Activation of Nrf2 by Cancer Chemotherapeutic Agents

Genome-wide Global Identification of NRF2 Binding Sites in A549 Non-Small Cell Lung Cancer Cells by ChIP-Seq Reveals NRF2 Regulation of Genes Involved in Focal Adhesion Pathways

Convenient Retinoid X Receptor Binding Assay Based on Fluorescence Change of the Antagonist NEt-C343

Identification of Retinoic Acid As an Inhibitor of Transcription Factor Nrf2 Through Activation of Retinoic Acid Receptor Alpha

Luteolin Inhibits Nrf2 Leading to Negative Regulation of the Nrf2/Are Pathway and Sensitization of Human Lung Carcinoma A549 Cells to Therapeutic Drugs

Supplementary Data from Targeting the HuR Oncogenic Role with a New Class of Cytoplasmic Dimerization Inhibitors

Supplementary Figures and Tables from Preclinical Characterization of XL092, a Novel Receptor Tyrosine Kinase Inhibitor of MET, VEGFR2, AXL, and MER

Supplementary Methods from the CRTC1-NEDD9 Signaling Axis Mediates Lung Cancer Progression Caused by LKB1 Loss

NRF2 inhibitors: Recent progress, future design and therapeutic potential